Trial Profile
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms RadVax
- 21 Apr 2023 Planned End Date changed from 23 Feb 2025 to 31 Dec 2025.
- 21 Apr 2023 Planned primary completion date changed from 23 Feb 2024 to 30 Jun 2024.
- 28 Mar 2022 Planned End Date changed from 23 Feb 2023 to 23 Feb 2025.